Journal article
Phase I/II trials of 186Re-HEDP in metastatic castration-resistant prostate cancer: post-hoc analysis of the impact of administered activity and dosimetry on survival
Abstract
PurposeTo investigate the role of patient-specific dosimetry as a predictive marker of survival and as a potential tool for individualised molecular radiotherapy treatment planning of bone metastases from castration-resistant prostate cancer, and to assess whether higher administered levels of activity are associated with a survival benefit.MethodsClinical data from 57 patients who received 2.5–5.1 GBq of 186Re-HEDP as part of NIH-funded phase …
Authors
Denis-Bacelar AM; Chittenden SJ; Dearnaley DP; Divoli A; O’Sullivan JM; McCready VR; Johnson B; Du Y; Flux GD
Journal
European Journal of Nuclear Medicine and Molecular Imaging, Vol. 44, No. 4, pp. 620–629
Publisher
Springer Nature
Publication Date
April 2017
DOI
10.1007/s00259-016-3543-x
ISSN
1619-7070
Associated Experts
Fields of Research (FoR)
Medical Subject Headings (MeSH)
Bone NeoplasmsClinical Trials, Phase I as TopicClinical Trials, Phase II as TopicEtidronic AcidHumansMaleOrganometallic CompoundsProstatic Neoplasms, Castration-ResistantRadiation DosageRadiopharmaceuticalsRadiotherapy DosageRadiotherapy Planning, Computer-AssistedSurvival AnalysisTomography, Emission-Computed, Single-Photon